Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $1.98B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.41M
Average 1.23M
IMNM Interest Income
Income earned on cash, deposits, and investments held by the company.
Immunome, Inc.NASDAQ: IMNM
Interest Income · Q3 FY2026 · quarter ended Sep 2026
Interest income growth accelerates
Q3 FY2026 interest income of $4.58M rose 70.8% year over year, ahead of the +57.2% change in trailing-twelve-month interest income. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at +1228.3% a year.
Context
- Interest income amounted to 168.8% of revenue in FY2025, up 26.9 pp from a year earlier.
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +70.8% holds above the trailing-twelve-month pace of +57.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 11.72M USD
- Year-over-year change
- -8.7%
- 4-year CAGR
- +485.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.72M | -8.7% |
| FY2024 | 2024-12-31 | 12.84M | +371.3% |
| FY2023 | 2023-12-31 | 2.72M | +54380.0% |
| FY2022 | 2022-12-31 | 5K | -50.0% |
| FY2021 | 2021-12-31 | 10K | — |
Interest Income vs competitors
How IMNM compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +57.2% is the 2nd highest of 11, against a peer median of -30.0%.
- Over three fiscal years its annual growth of +1228.3% compares with a peer median of +64.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $25.4M USD | -19.9% | +114.3% | 22679.5% | |
| LTM Mar 2026 | $24.93M USD | -32.8% | +70.4% | 39.3% | |
| LTM Sep 2026 | $18.04M USD | +57.2% | +1228.3% | — | |
| LTM Mar 2026 | €15.3M EUR | -36.7% | +90.7% | 41.0% | |
| LTM Mar 2026 | $14.94M USD | -30.5% | +63.7% | 3.9% | |
| LTM Mar 2026 | $11.63M USD | -10.2% | — | — | |
| LTM Mar 2026 | $7.7M USD | -80.3% | +38.9% | 7.7% | |
| LTM Mar 2026 | $5.93M USD | -29.4% | +26.0% | 3.8% | |
| LTM Sep 2026 | $3.68M USD | +270.3% | +64.5% | — | |
| LTM Mar 2026 | $1.12M USD | +24.8% | — | — | |
| LTM Mar 2026 | -$525K USD | -125.8% | +56.5% | — | |
| Peer median (excluding IMNM) | — | -30.0% | +64.1% | 23.5% | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$16.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.